NICE approves Alectinib as first line treatment for ALK-translocated NSCLC
July 2018 By Tom Newsom-Davis, Consultant Oncologist NICE has just approved Alectinib as first line treatment for ALK-translocated NSCLC. https://www.nice.org.uk/guidance/gid-ta10206/documents/final-appraisal-determination-document This is exciting news for patients with this comparatively rare type of lung cancer. Currently the standard of care in the … Read More